Navigation Links
Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference
Date:11/2/2007

and/or ARB received (as a percentage of the maximum FDA recommended dose). The benefit of XL784 compared to placebo increased with increasing dose of ACEi and/or ARB. In the subgroup of subjects treated with maximum recommended doses of ACEi and/or ARB, the difference between XL784 and placebo was 23% (p=0.13) for the primary analysis population.

XL784 was generally well-tolerated, with fewer subjects reporting adverse events in the XL784 group (77%) than in the placebo group (85%). Serious adverse events (SAEs) were reported by 9.5% of subjects in the XL784 group and by 11% of subjects in the placebo group. No SAEs in the XL784 group were considered to be related to study drug.

"We are pleased to report the data from the XL784 trial in patients with diabetic nephropathy," said George A. Scangos, PhD, president and chief executive officer of Exelixis. "While the trial did not meet its primary endpoint, various subgroup analyses suggest that the compound may have the potential to benefit patients with this disease. We submitted the XL784 data package to GSK on October 22, 2007 and expect to communicate future plans for XL784 once GSK has reached a decision on its interest in further developing the compound."

The previously announced briefing to be held today in conjunction with the presentation of the data for XL784 has been cancelled. However, we expect to discuss the data during the live webcast of our third quarter financial results and general business updates to be held on Monday, November 5, 2007 at 2:00 p.m. PST/5:00 p.m. EST. The webcast may be accessed in the Event Calendar page under Investors at http://www.exelixis.com. In addition, we will discuss the data for XL784 at our Third Annual R&D Day on December 5, 2007 to be held in New York.

About XL784

XL784 is the first small molecule compound developed by Exelixis using its proprietary drug discovery engine. The compound is a
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SAN DIEGO , July 31, 2014  Sorrento Therapeutics, ... death of Mr. Amar Singh , Chief Business Officer ... of apparent natural causes on July 30. "Sorrento ... dear friend and colleague. Our immediate thoughts go to Amar,s ... President and Chief Executive Officer. Mr. Singh ...
(Date:7/31/2014)... Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... Insulin Pump, today reported its financial results for the quarter ... second quarter of 2014 to the same period of 2013: ... $5.5 million , t:slim Pump shipments grew 64 percent ... six months ended June 30, 2014 to the same period ...
(Date:7/31/2014)... 31, 2014 Nektar Therapeutics (Nasdaq: NKTR ... ended June 30, 2014. Cash and investments ... as compared to $309.1 million at March 31, 2014."The second ... as we look forward to significant milestones for a number ... and Chief Executive Officer of Nektar. "The first of these ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14
... , THOUSAND OAKS, Calif., Dec. 3 Each year, hundreds ... Europe participate in the Amgen Scholars Program to gain hands-on ... universities. Now, the Amgen Scholars - past, present and ... Scholars Community at www.amgenscholars.com . , "The new ...
... MARQUETTE, Mich., Dec. 3 Pioneer Surgical Technology, Inc., ... awards in the Cervical Spine Care category at the ... Francisco, California in conjunction with the North American Spine ... receiving awards were the NuNec® Cervical Total Disc replacement ...
Cached Medicine Technology:New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists 2New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists 3Pioneer(R) Surgical Technology, Inc. Receives Prestigious Spine Technology Awards 2
(Date:8/1/2014)... OR (PRWEB) August 01, 2014 In ... called hydrotherapy – was fundamental to the practice of ... water researcher Sharon Kleyne, water therapy has been relegated ... time when climate change, water shortages, drought and pollution ... diseases, the Sharon Kleyne Hour Power of Water host ...
(Date:8/1/2014)... According to the Suspension Revolution 2.0 PDF review recently ... and women who want to get ripped abdominals within a ... 27 intense workouts that help blast fat and gain muscle ... Suspension Revolution 2.0 program provides users with easy tips and ... plans that help keep fit and stay healthy ...
(Date:8/1/2014)... August 01, 2014 Blindness is a ... that the scientists of today, despite well-meaning efforts, still have ... a definite treatment for reversing blindness that does not involve ... this is where alternative medicine takes the “slack” from the ... expensive treatments or harmful surgeries. , Alternative health specialist ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Online retailer ... offering a low price guarantee on their inventory of ... adult diapers, wipes, and pads along with other personal ... can be to find a line of incontinence products ... you find one that works for you, you shouldn't ...
(Date:8/1/2014)... York, US (PRWEB) August 01, 2014 ... DataSite in partnership with PitchBook presents the 3Q 2014 ... all U.S private equity investment, exits and fundraising activity ... useful insight to help plan for private equity endeavors ... the registration form to download it now. , About ...
Breaking Medicine News(10 mins):Health News:Water Researcher Advocates Reevaluation of 18th and 19th Century Water Therapy Movement 2Health News:Water Researcher Advocates Reevaluation of 18th and 19th Century Water Therapy Movement 3Health News:Suspension Revolution 2.0 PDF Review Exposes Dan Long's Program For Building Muscle – Vkool.com 2Health News:Suspension Revolution 2.0 PDF Review Exposes Dan Long's Program For Building Muscle – Vkool.com 3Health News:The Miracle Cure Review | The Unbeatable Secret to Reversing Any Vision Problem – Vinamy.com 2Health News:Disposable Medical Express Offering Low Price Guarantee On Tranquility Products 2Health News:Register to Download Merrill DataSite's Report: PitchBook 3Q 2014 Private Equity Breakdown Report 2
... of a recent study researchers say weight gain after age ... for postmenopausal women who // are not taking hormone replacement ... ages 50 to 74, by asking them about their weight ... women have been periodically asked to provide updates on their ...
... in as little as two days of physical inactivity, the ... and other related diseases.// ,Researchers conducted a study in ... stayed inactive. When the rats stopped running for two days ... of sugar taken into the muscle in response to insulin ...
... New research suggests weight loss may be an early ... loss begins before the onset of // definite dementia ... ,Weight loss in the elderly is common and may ... been documented in people who already have dementia. For ...
... surgery may be at higher risk for bone fractures, say ... For the study, nearly 20 percent of men treated with ... diagnosis, compared to about 13 percent of men who did ... given to men with locally advanced cancers and the therapy ...
... estrogen may provide protection against colon cancer. For the ... and followed their progress for one year. The diets were ... one contained milk protein, and diet two had soy protein. ... diets contained soy protein with the addition of an estrogen ...
... genetic discovery could help give insight into a very deadly ... that codes for the progesterone receptor increase a woman’s risk ... to a higher ovarian cancer risk as well as a ... used biological samples from an ongoing study and examined the ...
Cached Medicine News:
The CGPL capsulotomy contact glass was designed by Riquin, Fankhauser et al. for the dissection of opacified posterior lens capsules and membranes in the pupillary and retropupillary space with the Y...
The CGAL gonioscopic contact glass was designed by Roussel and Fankhauser for,laser treatments of the chamber angle. It reduces the laser spot by a factor of 1.5 as compared to a Goldmann Glass....
The CGRL is a Wide Angle Contact Glass designed for laser photocoagulation and diagnosis of the retina....
The classic Goldmann Glass. Designed to work with argon/YAG Lasers....
Medicine Products: